Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial-Reference-Cited by-同舟云学术

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Published:2010-10 Issue:10 Volume:11 Page:934-941
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mateos María-Victoria,Oriol Albert,Martínez-López Joaquín,Gutiérrez Norma,Teruel Ana-Isabel,de Paz Raquel,García-Laraña José,Bengoechea Enrique,Martín Alejandro,Mediavilla Joaquín Díaz,Palomera Luis,de Arriba Felipe,González Yolanda,Hernández Jose-Mariano,Sureda Ana,Bello José-Luis,Bargay Joan,Peñalver Francisco-Javier,Ribera José-María,Martín-Mateos María-Luisa,García-Sanz Ramón,Cibeira María-Teresa,Ramos María-Luisa Martín,Vidriales María-Belén,Paiva Bruno,Montalbán María-Angeles,Lahuerta Juan-José,Bladé Joan,Miguel Jesús-Fernando San

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens;Alexanian;JAMA,1969

2. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial;Palumbo;Lancet,2006

3. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial;Facon;Lancet,2007

4. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annual Meeting 2007; Atlanta, GA, USA; Nov 16, 2007. 78 (abstr).

5. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study;Wijermans;J Clin Oncol,2010

Cited by 417 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

2. Prognostic frailty-based determinants of long-term mortality in older patients with newly diagnosed multiple myeloma;2024-08-20

3. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

4. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial;Nature Medicine;2024-06-03

5. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis;Blood Cancer Journal;2024-03-22